Glucagon analogues
US9988429B2 · kind B2 · utility
11Cited by
9References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 16, 2014 |
| Grant date | Jun 5, 2018 |
| Priority date | — |
| Expiry date | Oct 16, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.